Emery Pharma

Portola Pharmaceuticals is a Bay Area–based pharmaceuticals company with a focus on bioresearch and drug development. Their efforts are directed towards global markets, specifically in the treatment of cardiovascular disease and inflammation. Generated from their available business information

Exelixis is an integrated drug discovery and development company. The company utilizes cutting-edge genomic, molecular biology and combinatorial chemistry technologies to develop innovative therapies for significant human diseases. Its primary mission is to improve patient care by developing proprietary human therapeutics that target the complex molecular causes of disease. Exelixis has built a research and discovery platform. The Exelixis clinical development pipeline includes compounds in cancer and renal disease. The company s pre-clinical pipeline is comprised of six programs. The pre-clinical oncology programs consist of development candidates that focus on inhibiting kinases. In its pre-clinical metabolic disease programs, Exelixis has developed small molecules that modulate nuclear hormone receptors that implicate various metabolic and cardiovascular disorders. Corporate headquarters are in San Francisco. The research facility is in Portland, Ore.

Corcept Therapeutics is a pharmaceutical firm engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. The company s lead product candidate, Corlux, is in clinical trials for the treatment of the psychotic features of psychotic major depression. PMD is a disorder that affects nearly three million people in the United States annually. The U.S. Food and Drug Administration has granted fast-track status to Corcept Therapeutics program. The company is headquartered in Menlo Park, Calif.